JY
RXRX icon

Jeff Yass’s Recursion Pharmaceuticals RXRX Stock Holding History

Jeff Yass’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.3M Buy
3,347,700
+715,500
+27% +$2.38M ﹤0.01% 3065
2026
Q1 		$8.08M Buy
2,632,200
+424,500
+19% +$1.64M ﹤0.01% 3448
2025
Q4 		$9.03M Buy
2,207,700
+173,500
+9% +$859K ﹤0.01% 3186
2025
Q3 		$9.93M Sell
2,034,200
-335,500
-14% -$1.76M ﹤0.01% 3048
2025
Q2 		$12M Buy
2,369,700
+946,600
+67% +$4.65M ﹤0.01% 2602
2025
Q1 		$7.53M Buy
1,423,100
+431,200
+43% +$3.14M ﹤0.01% 2918
2024
Q4 		$6.71M Buy
991,900
+400,400
+68% +$2.69M ﹤0.01% 3166
2024
Q3 		$3.9M Buy
591,500
+288,000
+95% +$2.06M ﹤0.01% 4051
2024
Q2 		$2.28M Sell
303,500
-19,100
-6% -$167K ﹤0.01% 4847
2024
Q1 		$3.22M Buy
322,600
+24,800
+8% +$276K ﹤0.01% 4380
2023
Q4 		$2.94M Buy
297,800
+76,200
+34% +$543K ﹤0.01% 4613
2023
Q3 		$1.7M Buy
221,600
+150,900
+213% +$1.51M ﹤0.01% 5472
2023
Q2 		$528K Buy
70,700
+27,700
+64% +$194K ﹤0.01% 8184
2023
Q1 		$287K Buy
43,000
+32,900
+326% +$261K ﹤0.01% 9824
2022
Q4 		$77.9K Sell
10,100
-53,200
-84% -$522K ﹤0.01% 11147
2022
Q3 		$674K Buy
63,300
+36,600
+137% +$371K ﹤0.01% 7674
2022
Q2 		$217K Buy
+26,700
New +$179K ﹤0.01% 10441
2021
Q4 		– Sell
-16,700
Closed -$384K – 13799
2021
Q3 		$384K Buy
+16,700
New +$473K ﹤0.01% 10029

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jeff Yass's RXRX Position: Q2 2026 in Review

Jeff Yass reduced its Recursion Pharmaceuticals (RXRX) stake by 22% in Q2 2026, selling an estimated $3.11M and leaving 3,292,128 shares worth $12.1M. The position accounts for ﹤0.01% of the portfolio, ranked #3095.

Jeff Yass first reported a position in RXRX in Q2 2021 and has held it in 21 quarters since. The position peaked at $26.3M in Q3 2025. 340 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Jeff Yass held 3,292,128 shares of Recursion Pharmaceuticals worth $12.1M as of Q2 2026.
  • Jeff Yass sold 933,149 Recursion Pharmaceuticals shares in Q2 2026, an estimated $3.11M.
  • Recursion Pharmaceuticals made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #3095 holding.
  • Jeff Yass first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 21 quarters since.
  • Jeff Yass's Recursion Pharmaceuticals position peaked at $26.3M in Q3 2025.
  • 340 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.